Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. provides devices, implants, and services for the treatment of peripheral vascular disease. The company develops, manufactures, and markets disposable and implantable vascular devices for vascular surgeons, with products used in arteries and veins.
Recurring LMAT news includes quarterly financial results, guidance, dividend declarations, and management presentations at healthcare investor conferences. Company updates also discuss product categories such as Artegraft, grafts, valvulotomes, and carotid shunts, along with sales activity across the Americas, EMEA, and Asia Pacific.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
LeMaitre Vascular (LMAT) has secured an exclusive distribution agreement for Aziyo Biologics' cardiovascular patches in the U.S. for three years, with an option to acquire Aziyo's worldwide cardiovascular patch business during the second and third year. The patches, including ProxiCor®, VasCure®, and Tyke®, utilize an extracellular matrix aimed at reducing inflammation and promoting healthy tissue formation. Aziyo reported $6.8 million in sales from these patches in 2022. LeMaitre anticipates a 50% gross margin from patch sales. President David Roberts expressed enthusiasm about enhancing the company's product offerings for vascular and cardiac surgeons. Further financial implications of this agreement will be detailed in LeMaitre’s Q1 2023 earnings call on May 2, 2023.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will announce its Q1 2023 financial results on May 2, 2023, after market closure. A conference call is scheduled for 5:00 PM ET on the same day to discuss the results and outlook for the company. Interested parties can register for the call here. The company provides devices and services for treating peripheral vascular disease, impacting over 200 million people globally, and focuses on the needs of vascular surgeons.
LeMaitre Vascular (Nasdaq: LMAT) announced the acquisition of its Thai distributor, Prompt Serve, for $688,000. In 2022, Prompt Serve sold approximately $1.5 million of LeMaitre products to Thai hospitals. This acquisition will enable LeMaitre to establish a direct sales presence in Thailand, marking its 29th direct-to-hospital country and 8th in the APAC region. Jacob Petersen, VP of Asia-Pacific, noted this move is part of their ongoing expansion, aiming for over 90% of operations to be direct in the APAC market. Further financial guidance regarding the impact on 2023 revenue and earnings will be provided during the Q1 earnings call.